Videos

Dr. Jason Mouabbi discusses remaining unmet needs and practical considerations in the management of PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi discusses how available pathway-directed treatment approaches may be differentiated for patients with biomarker-selected HR-positive/HER2-negative advanced breast cancer, with consideration of treatment setting and toxicity profiles.

Dr. Jason Mouabbi returns to the patient case, noting improvement in the patient's osseous lesions and resolution of back pain after 3 months of treatment.

Dr. Jason Mouabbi discusses how to approach adverse-event attribution when treating patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer with a multidrug regimen.

Dr. Jason Mouabbi discusses additional adverse events that require attention when managing patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer receiving combination therapy.

Dr. Jason Mouabbi revisits the patient's Grade 2 hyperglycemia at week 6, when fasting glucose reaches 212 mg/dL.

Dr. Jason Mouabbi discusses the approach to managing treatment-related hyperglycemia while maintaining cancer treatment for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi reviews the treatment initiation and early glucose monitoring strategy for a patient with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer receiving inavolisib in combination with palbociclib and fulvestrant.

Dr. Jason Mouabbi discusses strategies for assessing and managing the risk of treatment-related hyperglycemia before initiating therapy for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

Dr. Jason Mouabbi presents a 59-year-old postmenopausal woman with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer who develops metastatic disease 8 months after completing adjuvant endocrine therapy.

Theodore Wagener, PhD, discusses psychedelics beyond depression in cancer, including neuropathy and chemo brain, and why he expects cancer centers to adopt them.

Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer.

Allogeneic and in vivo CAR T therapies simplify manufacturing and delivery, potentially expanding access to cellular therapy beyond specialized centers.

Amer M. Zeidan, MBBS, MHS, on how genetics, comorbidities, and goals of care guide acute myeloid leukemia treatment selection in real-world practice.

CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, while CAR T and pivotal trials reshape strategy.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, reviews efficacy results from the fully enrolled cohort 1 of the phase 1b/2 OrigAMI-4 study, published in the Journal of Clinical Oncology in 2026.

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, outlines the design of the phase 1b/2 OrigAMI-4 study, an umbrella trial evaluating subcutaneous amivantamab across multiple settings in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), including first-line disease, platinum-refractory disease, and platinum-and-immune-checkpoint-inhibitor (ICI)-refractory disease.

Paula Rodriguez-Otero, MD, discusses findings from the LINKER-SMM1 trial presented at the IMS Annual Meeting.

Eytan M. Stein, MD, explains how real-world data complements AML trials and where targeted agent combinations and immunotherapy research must go next.

Martin Dietrich, MD, PhD, names testing as the first gap that remains, followed by a limited understanding of how resistance develops and when to retest.

Luciano Costa, MD, PhD, explains the findings from a competing risk analysis of the MajesTEC-3 trial linking survival to reduced myeloma progression.

Daniel Heng, MD, discusses the FDA approval of belzutifan plus lenvatinib in RCC, managing hypoxia and anemia, and how it may affect treatment sequencing.

Jorge Nieva, MD, discusses how long-term responses in ROS1+ non–small cell lung cancer affect imaging frequency, MRD testing, and treatment intensification.

Jorge Nieva, MD, reviews long-term taletrectinib data in ROS1+ non–small cell lung cancer, including about 90% response rates across fusion partners and manageable safety.

Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.

Andrew Kuykendall, MD, discusses where rusfertide may fit in polycythemia vera, from replacing phlebotomy to use with cytoreductive therapy and fatigue.

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.

Daniel DeAngelo, MD, PhD, discusses how TKIs have given patients with CML a full lifespan and what is being done to build on the incredible progress in this setting.

Giada Bianchi, MD, discusses tailoring therapy in myeloma, addressing ultra-high-risk disease, and amyloidosis becoming a chronic condition at IMS 2026.

Dr. Jason Mouabbi discusses the role of molecular testing in guiding treatment selection for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.